Abstract
Acute myocardial infarction (AMI) results in systolic dysfunction, myocarditis and fibrotic remodeling, which causes irreversible pathological remodeling of the heart. Associated cell death and inflammation cause cytokine release, which activates the p38 MAPK signaling pathway to propagate damaging signals via MAPKAP kinase 2 (MK2). Previously we showed that intraperitoneal injection of a cell permeable peptide inhibitor of MK2, MMI-0100, protects against fibrosis, apoptosis and systolic dysfunction in a mouse model of AMI induced by left-anterior descending coronary artery (LAD) ligation. Here we tested a new route of administration of MMI-0100: inhalation of nebulized peptide. When given within 30 min of AMI and daily for 2 weeks thereafter, both inhaled and injected MMI-0100 improved cardiac function as measured by conscious echocardiography. Limited fibrosis was observed after 2 weeks by Massons trichrome staining, suggesting that MMI-0100 protects the heart prior to the formation of significant fibrosis. These results support a nebulized route of administration of MMI-0100 can protect the myocardium from ischemic damage.
This is a preview of subscription content, log in via an institution to check access.
References
Arabacilar P, Marber M (2015) The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front Pharmacol 6:102. doi:10.3389/fphar.2015.00102
Bassi R, Heads R, Marber MS, Clark JE (2008) Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr Opin Pharmacol 8:141–146. doi:10.1016/j.coph.2008.01.002
Maejima Y et al (2013) Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med 19:1478–1488. doi:10.1038/nm.3322
Qian L et al (2012) In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485:593–598. doi:10.1038/nature11044
Shiroto K, Otani H, Yamamoto F, Huang CK, Maulik N, Das DK (2005) MK2−/− gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. J Mol Cell Cardiol 38:93–97. doi:10.1016/j.yjmcc.2004.10.018
Vidyasagar A, Wilson NA, Djamali A (2012) Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair 5:7. doi:10.1186/1755-1536-5-7
Vittal R et al (2013) Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 49:47–57. doi:10.1165/rcmb.2012-0389OC
Ward B, Seal BL, Brophy CM, Panitch A (2009) Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J Pept Sci 15:668–674. doi:10.1002/psc.1168
Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C (2007) Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 100:456–459. doi:10.1161/01.RES.0000259559.48597.32
Willis MS, Schisler JC, Li L, Rodriguez JE, Hilliard EG, Charles PC, Patterson C (2009) Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 105:80–88. doi:10.1161/CIRCRESAHA.109.194928
Willis MS et al (2014) Muscle ring finger 1 and muscle ring finger 2 are necessary but functionally redundant during developmental cardiac growth and regulate E2F1-mediated gene expression in vivo. Cell Biochem Funct 32:39–50. doi:10.1002/cbf.2969
Xu L et al (2014) MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition. J Mol Cell Cardiol 77:86–101. doi:10.1016/j.yjmcc.2014.09.011
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Rights and permissions
About this article
Cite this article
Brown, D.I., Cooley, B.C., Quintana, M.T. et al. Nebulized Delivery of the MAPKAP Kinase 2 Peptide Inhibitor MMI-0100 Protects Against Ischemia-Induced Systolic Dysfunction. Int J Pept Res Ther 22, 317–324 (2016). https://doi.org/10.1007/s10989-015-9507-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-015-9507-3